Puyraimond-Zemmour, Déborah
Granger, Benjamin
Molto, Anna
Gaujoux-Viala, Cécile
Guillemin, Francis
Ruyssen-Witrand, Adeline
Dougados, Maxime
Fautrel, Bruno
Gossec, Laure
Article History
Received: 9 August 2018
Accepted: 4 February 2019
First Online: 19 February 2019
Ethics approval and consent to participate
: these studies fulfilled current good clinical practice, obtained the approval of the appropriate ethical committees, and participants gave their written informed consent. Databases locked in February 2017 for DESIR and June 2017 for ESPOIR were used.
: Not applicable.
: L. Gossec received research grants from Pfizer and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Pfizer, Roche, and UCB. A. Molto received research grants from Pfizer, UCB, and Merck and consulting fees from AbbVie, Bristol-Myers Squibb, Janssen, Novartis, Pfizer, and UCB. F. Guillemin received research grants from his institution, Genevrier, Sanofi. B. Fautrel received consulting fees from AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, Medac, MSD, NORDIC Pharma, Novartis, Pfizer, Roche, Sanofi-Aventis, SOBI, and UCB. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.